AMF Pensionsforsakring AB grew its holdings in Humana Inc (NYSE:HUM) by 5.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,256 shares of the insurance provider’s stock after purchasing an additional 6,412 shares during the quarter. AMF Pensionsforsakring AB owned about 0.09% of Humana worth $31,373,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Destination Wealth Management increased its holdings in shares of Humana by 130.0% during the 1st quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock worth $31,000 after buying an additional 65 shares during the last quarter. Zions Bancorporation N.A. acquired a new stake in shares of Humana during the 1st quarter worth approximately $51,000. Berman Capital Advisors LLC increased its holdings in shares of Humana by 152.3% during the 1st quarter. Berman Capital Advisors LLC now owns 217 shares of the insurance provider’s stock worth $57,000 after buying an additional 131 shares during the last quarter. Horan Capital Advisors LLC. acquired a new stake in shares of Humana during the 1st quarter worth approximately $65,000. Finally, Moody National Bank Trust Division increased its holdings in shares of Humana by 153.4% during the 1st quarter. Moody National Bank Trust Division now owns 261 shares of the insurance provider’s stock worth $69,000 after buying an additional 158 shares during the last quarter. 91.33% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently issued reports on the stock. UBS Group raised their price target on shares of Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. SunTrust Banks lifted their target price on shares of Humana to $340.00 and gave the company a “hold” rating in a report on Thursday, August 1st. ValuEngine upgraded shares of Humana from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Morgan Stanley dropped their target price on shares of Humana from $331.00 to $315.00 and set an “overweight” rating for the company in a report on Friday, July 12th. Finally, Piper Jaffray Companies lifted their target price on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $342.26.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $5.24 by $0.81. The business had revenue of $16.25 billion during the quarter, compared to the consensus estimate of $15.88 billion. Humana had a net margin of 4.13% and a return on equity of 22.47%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.96 earnings per share. As a group, analysts forecast that Humana Inc will post 17.63 earnings per share for the current fiscal year.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: Cost of Capital
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.